Back to top

biotechnology: Archive

Zacks Equity Research

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTAPositive Net Change

Ahan Chakraborty

Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

NVONegative Net Change MRKNegative Net Change LLYPositive Net Change

Zacks Equity Research

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

NVSNegative Net Change BAYRYNegative Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.

BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change

Zacks Equity Research

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

REGNNegative Net Change NVSNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change

Zacks Equity Research

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

ALKSNegative Net Change EXELPositive Net Change VRNAPositive Net Change KNSAPositive Net Change

Zacks Equity Research

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

AGENPositive Net Change VRNAPositive Net Change APLSPositive Net Change IMCRPositive Net Change

Ahan Chakraborty

Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?

Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.

SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change

Ekta Bagri

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

EXELPositive Net Change ALKSNegative Net Change VRNAPositive Net Change KNSAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

BIIBNegative Net Change AGENPositive Net Change VRNAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?

INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.

GSKNegative Net Change NVSNegative Net Change QGENNegative Net Change INCYPositive Net Change

Zacks Equity Research

Company News for Jul 1, 2025

Companies In The News Are: META, MRNA, HOOD, AAPL.

AAPLPositive Net Change MRNAPositive Net Change METAPositive Net Change HOODNegative Net Change

Zacks Equity Research

RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome

Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.

BAYRYNegative Net Change AGENPositive Net Change RAREPositive Net Change IMCRPositive Net Change